Canada's Zymeworks 2025 revenue rises 39%
Overview
Biotechnology firm's 2025 revenue rose 39% yr/yr, driven by clinical milestones
Net loss for 2025 reduced by 34% compared to previous year
Company utilized $62.5 mln for share repurchases under current program
Outlook
Zymeworks expects adjusted operating expenses in 2026 to be 20% lower than 2025
Company anticipates regulatory milestone payments to fund operations beyond 2028
Zymeworks remains focused on timely execution of its novel strategy in 2026
Result Drivers
MILESTONE ACHIEVEMENTS - Revenue growth in 2025 was primarily driven by significant clinical and regulatory milestones achieved through collaborations with partners such as J&J and BeOne
ROYALTY TRANSITION - Transition of zanidatamab clinical activities to Jazz expected to reduce development-support revenue but increase royalty revenue over time
ROYALTY-BACKED FINANCING - $250 mln royalty-backed note financing with Royalty Pharma to support share repurchases and potential acquisitions
Company press release: ID:nGNXc8SC3P
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Basic EPS |
| -$0.55 |
|
Q4 Operating Expenses |
| $46.67 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zymeworks Inc is $34.00, about 46% above its February 27 closing price of $23.29
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
JPMorgan Warns Hormuz Blockade Risks Oil Shutdown in 25 Days, But How Will the US-Iran Conflict Shape Global Oil Prices?
TradingKey - Following the announcement on the night of February 28 banning all vessels from passing through the Strait of Hormuz, JPMorgan Chase issued a warning: if the Strait of Hormuz is completely blocked, the combined onshore and offshore storage capacity of Middle Eastern oil-producing nation
US-Iran Conflict Ignites, Global Arms Race Heats Up, Will Defense Stocks See a New Round of Gains?
TradingKey - On February 28 local time, the United States and Israel launched joint large-scale airstrikes against Iran, targeting its nuclear facilities, missile industry, and naval forces. This marks another sharp escalation in the conflict following the US military strikes on Iranian nuclear facilities in June last year. The military operation not only exacerbates already strained geopolitical tensions but has also sent shockwaves through global capital markets, which is expected to further boost defense stocks.
U.S.-Iran Conflict Escalates. Strait of Hormuz Shutdown, How Much Room for Oil Prices to Rise?
TradingKey - A sharp escalation in geopolitical risks has directly triggered intense volatility in global crude oil markets. At the market open this Monday, WTI crude oil futures surged by over 11%, and Brent crude opened up 13%, though these gains subsequently narrowed.
Shiba Inu 2026: L3 Evolution & the Next Bull Run
Discover the Shiba Inu (SHIB) 2026 outlook as it evolves from a meme coin into a sophisticated L3 utility network. This analysis covers the critical $0.00000589 support level, the impact of U.S. government SHIB holdings, and the Shibarium update featuring FHE privacy. Explore the "next Shiba Inu" bu
How Tesla Survives the Cold Winter, Will Tesla Stock Continue to Fall in 2026?
TradingKey — Recently, weighed down by earnings missing expectations and factors such as AI bubble and disruption theories, Tesla (TSLA) shares have continued to slide, falling nearly 20% from their December 2025 peak.
